Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Gastroenterology
; 145(2): 329-38.e1, 2013 Aug.
Article
en En
| MEDLINE
| ID: mdl-23583433
Palabras clave
Clinical Trial; DOR; Drug; EQ-5D; EuroQoL-5 Dimension; FDA; Functional Bowel Disorders; GLMM; IBS; IBS-D; IBS-QOL; IBS-Quality of Life; IBS-SSS; IBS-Symptom Severity Score; IVRS; MOR; Transit; US Food and Drug Administration; WAP; generalized linear mixed effects model; interactive voice response system; irritable bowel syndrome; irritable bowel syndrome with diarrhea; worst abdominal pain; δ opioid receptor; µ opioid receptor
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fenilalanina
/
Fármacos Gastrointestinales
/
Receptores Opioides delta
/
Receptores Opioides mu
/
Síndrome del Colon Irritable
/
Diarrea
/
Imidazoles
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Aspecto:
Patient_preference
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Gastroenterology
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos